XML 49 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equity
 9 Months Ended
Sep. 30, 2017
Equity [Abstract]  
Equity
Equity
Total equity as of September 30, 2017, increased $720.3 million compared to December 31, 2016. This increase was primarily driven by net income attributable to Biogen Inc. of $2.8 billion, partially offset by share repurchases totaling approximately $1.4 billion, as described below, and an adjustment to retained earnings of $852.8 million reflecting the spin-off of our hemophilia business, as described in Note 3, Hemophilia Spin-Off, to these condensed consolidated financial statements.
Share Repurchases
In July 2016 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock. This authorization does not have an expiration date. All share repurchases under this authorization will be retired. Under this program, we repurchased and retired 3.7 million shares of common stock at a cost of $1.0 billion during the nine months ended September 30, 2017. We did not repurchase any shares of common stock under this program during the three months ended September 30, 2017. During the three and nine months ended September 30, 2016, we repurchased and retired 1.1 million shares of common stock at a cost of $348.9 million. As of September 30, 2017, approximately $3.0 billion remains available to repurchase shares under this authorization.
In February 2011 our Board of Directors authorized a program to repurchase up to 20.0 million shares of common stock, which was completed as of March 31, 2017. During the nine months ended September 30, 2017, we repurchased 1.3 million shares of common stock at a cost of $365.4 million under this program. We did not repurchase any shares of common stock under this program during the three and nine months ended September 30, 2016.
Noncontrolling Interests
The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):
 
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
(In millions)
2017
 
2016
 
2017
 
2016
NCI, beginning of period
$
(11.6
)
 
$
(0.1
)
 
$
(11.5
)
 
$
2.1

Net income (loss) attributable to NCI, net of tax
—

 
(2.7
)
 
(0.1
)
 
(5.8
)
Fair value of net assets and liabilities acquired and assigned to NCI
—

 
—

 
—

 
0.9

Translation adjustment and other
—

 
0.1

 
—

 
0.1

NCI, end of period
$
(11.6
)
 
$
(2.7
)
 
$
(11.6
)
 
$
(2.7
)